Soluble PD-L1 as an early marker of progressive disease on nivolumab by David F McDermott, Gordon J Freeman, Toni K Choueiri, Petra Ross-MacDonald, F Stephen Hodi, Megan Wind-Rotolo, Long Yuan, Kathleen M Mahoney, Linan Song, Eliseo Veras

Get full text

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma by Jin Yao, Thomas Powles, David F McDermott, Toni K Choueiri, Petra Ross-MacDonald, Simon Papillon-Cavanagh, Robert J Motzer, M Brent McHenry, Megan Wind-Rotolo, Ron Ammar, Yann-Alexandre Vano, Saurabh Gupta, Celine Han, Shruti S Saggi

Get full text

Mitapivat metabolically reprograms human β-thalassemic erythroblasts, increasing their responsiveness to oxidation by Angela Siciliano, Angelo D’Alessandro, Alessandro Matte, Giovanni Bisello, Mariarita Bertoldi, Monika Dzieciatkowska, Amy Argabright, Richard Huot Pozzetto, Veronica Riccardi, Andrea Mattarei, Alberto Ongaro, Jacopo Ceolan, Roberta Russo, Leonardo Rivadeneyra, Megan Wind-Rotolo, Achille Iolascon, Carlo Brugnara, Lucia De Franceschi

Get full text

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus... by David Gardiner, Jay Lalezari, Eric Lawitz, Michael DiMicco, Rheem Ghalib, K Rajender Reddy, Kyong-Mi Chang, Mark Sulkowski, Steven O' Marro, Jeffrey Anderson, Bing He, Vikram Kansra, Fiona McPhee, Megan Wind-Rotolo, Dennis Grasela, Mark Selby, Alan J Korman, Israel Lowy

Get full text